News

Say goodbye to ‘dementia’


 

EXPERT ANALYSIS FROM THE AAGP ANNUAL MEETING

Elevated homocysteine and C-reactive protein levels are implicated in cardiovascular disease and also increasingly under scrutiny in Alzheimer’s disease. High homocysteine levels can readily be lowered with folate, and 81 mg/day of aspirin may be sufficient to reduce C-reactive protein, he added.

"Delirium" is the one neurocognitive disorder that’s essentially unchanged from the DSM-IV, according to Dr. McCall and Dr. Grossberg. This condition is characterized by rapid onset and fluctuations in severity during the day and must be linked to the physiologic consequences of a medical condition.

Dr. McCall reported receiving research grants from the National Institute of Mental Health and Merck. Dr. Grossberg serves as a consultant to Forest Laboratories, Lundbeck, Novartis, Otsuka, and Takeda.

bjancin@frontlinemedcom.com

Pages

Recommended Reading

Intensive BP, lipid control didn’t alter cognitive decline in type 2 diabetes
MDedge Family Medicine
NIH and pharma partner on RA, lupus, diabetes, Alzheimer’s research
MDedge Family Medicine
Citalopram improves agitation in Alzheimer’s patients but has cardiac risks
MDedge Family Medicine
Alzheimer’s treatment requires ‘multiple shots on goal’ approach
MDedge Family Medicine
Plasma biomarker panel predicts amnestic MCI or Alzheimer’s
MDedge Family Medicine
Two definitions of Gulf War illness recommended
MDedge Family Medicine
Pseudobulbar affect: More common than you’d think
MDedge Family Medicine
USPSTF: Evidence still ‘insufficient’ to back cognitive impairment screening
MDedge Family Medicine
Hoarding: Not just a symptom of OCD
MDedge Family Medicine
Late-life depression can be dementia prodrome
MDedge Family Medicine